Protalix BioTherapeutics (PLX) Stock: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.71
0.03 (1.12%)
▲
5d:
-0.37%
30d:
+4.63%
90d:
+17.83%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PLX trades at premium valuation expecting 16.6% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: PLX trades at premium valuation expecting 16.6% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.71, which is considered fair relative to its 30-day fair value range of $2.55 to $2.76. From a valuation perspective, the stock is trading at a premium (Forward PE: 54.2) compared to its historical average (34.2). At these levels, the market is pricing in 16.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.60, while resistance sits at $2.85.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+305.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.60, while resistance sits at $2.85.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+305.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.55 -
$2.76
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 305.9% below Wall St target ($11.00)
- NEUTRAL: PE elevated vs history but 16.6% growth expectation is conservative given 2241% recent growth
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$2.55 -
$2.76
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.60
Resistance Level
$2.85
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
54.20
Wall Street Target
$11.00
(+305.9%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
2241.1%
Profit Margin
23.5%
Valuation Premium vs History
+16.6% premium
PE vs Historical
54.2 vs 34.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+16.6%
(market-implied from PE analysis)
1-Year Target
$3.16
(+17%)
2-Year Target
$3.68
(+36%)
3-Year Target
$4.30
(+59%)
3-Yr Target (if PE normalizes)
(PE: 54→34)
PE COMPRESSION
$2.71
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 54.2, Growth: -79.2%)
$1.98
(+-27%)
Base:
(SPY PE: 20.4, Growth: -79.2%)
$0.74
(-73%)
Bear:
(PE: 17.3, Growth: -79.2%)
$0.63
(-77%)
📈
Valuation based on Current Earnings
Trailing PE: 12.18 | Current EPS (TTM): $0.22
Bull Case
$1.47
(-46%)
Analyst growth -50.0%, PE expands to 13.4
Base Case
$1.34
(-51%)
Market implied -50.0%, PE stable at 12.2
Bear Case
$1.82
(-33%)
Severe decline -20.0%, PE contracts to 10.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
